Preventing big out-of-pocket expenditures by patients for health services and pharmaceuticals may be the antidote to the toxic bad publicity for health reform during August. At least, PhRMA hopes so. The trade association is helping to support an AMA campaign against copays.
Cole Werble
PhRMA enters the final round of Health Care Reform 2009 next week with two big victories in hand and a strong political alliance in line for a previously less visible...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Monitoring the use of decentralized elements in clinical trials is a priority for the European medicines regulatory network.
Pfizer told the Pink Sheet it would work with the health technology assessment institute, NICE, with the hope of making Hympavzi available to patients with hemophilia A via the National Health Service.
The European Medicines Agency has OKd 10 new medicines for EU-wide approval, including a CAR-T therapy for treating acute lymphoblastic leukemia. Two drugs were, however, rejected.
